Clinical Trial

Renal Efficacy and Safety of the Novel Oral Small-Molecule GLP-1RA HRS-7535 Evaluated in Participants With Chronic Kidney Disease

Study acronym: RENEW-CKD
Not Yet Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
This is a multicenter, randomized, double-blind, placebo-controlled, parallel-group and event-driven phase III clinical trial. The aim of this trial is to confirm the superiority of HRS-7535 over placebo in reducing the risks of renal outcomes and cardiovascular death among participants with chronic kidney disease (CKD) on the basis of standard of care
Trial Details
NCT Number NCT07625774
Lead Sponsor Shandong Suncadia Medicine Co., Ltd.
Conditions Chronic Kidney Disease
Enrollment 3,690 participants
Start Date 2026-07
Primary Completion 2031-05 (estimated)
Study Completion 2031-07 (estimated)
Updated on ClinicalTrials.gov 2026-06-04